Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694145 · ClinicalTrials.gov registry record
Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images
A clinical trial of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by Charles Drew University of Medicine and Science.
- Active
- Registry status
- 300
- Enrollment target
- 3
- Study locations
NCT03694145 is a study of Diabetic Macular Edema and Diabetic Retinopathy that is active but no longer recruiting, run by Charles Drew University of Medicine and Science. The registered enrollment target is 300 participants, below the 3,790-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03694145, a study of Diabetic Macular Edema and Diabetic Retinopathy, is active but no longer recruiting, sponsored by Charles Drew University of Medicine and Science.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to compare the results of a deep learning approach to diabetic retinopathy assessment with results from (1) an in-person examination with an ophthalmologist, and (2) the assessments of optometrists involved in a teleretinal screening program.
Conditions Studied
Interventions
- OTHER In-Person Eye Examination
Study Locations (3)
California
- Los Angeles Department of Public Health - Los Angeles
- University of California - Los Angeles - Los Angeles
- Charles R. Drew University of Medicine and Science - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-10-25 |
| Est. Completion | 2025-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694145
The ClinicalTrials.gov registry entry for NCT03694145 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,790-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (92% lower). The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which In-Person Eye Examination is the first listed.
NCT03694145 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03694145 about?
NCT03694145 is a clinical study titled "Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images". The objective of this study is to compare the results of a deep learning approach to diabetic retinopathy assessment with results from (1) an in-person examination with an ophthalmologist, and (2) the assessments of optometrists involved in a teleretinal screening program.
What is the current status of trial NCT03694145?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2018-10-25. Estimated completion is 2025-07-31.
What conditions does trial NCT03694145 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Retinopathy.
What interventions are being tested in trial NCT03694145?
The interventions under investigation include: In-Person Eye Examination (OTHER).
Who is sponsoring clinical trial NCT03694145?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03694145 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.